The clinical trials DivStress, DivHope, CogniDive and ObeDive highlight the profound and lasting impact of the Bathysmed protocol. These four studies attest to the versatility and effectiveness of the Bathysmed protocol, providing new hope and innovative solutions for those seeking to improve their mental and physical health.

There is a trend towards a greater decrease in the Bathysmed group compared to the controls (F=2.75; p=0.07) after three months
The DivHope study was largely funded by the Foundation for Victims of Terrorism. It was approved by the Southeast VI Ethics Committee on October 10, 2017, under the number NCT03332290
To learn more about the DivHope study, you can consult the complete study report, click here.The results, currently in press, show a significant decrease in emotional eating and perceived stress for the experimental group compared to the control group, not only at the end of the treatment exposure (M2) but also six months later (M8). Significant decrease in perceived stress levels (PSS - Cohen) for the Bathysmed group.
Significant decrease in perceived stress levels (PSS - Cohen) for the Bathysmed group.

A specific effect of the virtual reality device has also been demonstrated. These very positive results open up a new path in the treatment of obesity and offer hope for other stress-related disorders. The Obedive study was funded by Bathysmed with the assistance of BPI France. It received approval from the Ile-de-France III ethics committee on June 7, 2022, under the number RIPH2G: 22.01819.000151. The results of the study are available HERE
Navigation